Kymab
is a biotechnology firm that develops and commercializes human antibody-based therapeutics for the treatment of infectious diseases... Read moreKymab
is a biotechnology firm that develops and commercializes human antibody-based therapeutics for the treatment of infectious diseases... Read more
CEO
Add
News
Apr 09, 2021
PharmiWeb
Kymab: Sanofi completes Kymab acquisition
Jan 20, 2021
Asian Venture Capital Journal
Kymab: Deal focus: Monetizing mice
Jan 19, 2021
Global Legal Chronicle
Kymab: Sanofi's $1.1 Billion Acquisition Of Kymab
Jan 13, 2021
DealStreetAsia
Kymab: ORI Capital exits Kymab in $1.1b deal with Sanofi, hits first close of $400m second fund
Jan 13, 2021
Pulse2.0
Kymab: Why Sanofi Is Buying Kymab For Up To $1.45 Billion
Jan 13, 2021
Asian Venture Capital Journal
Kymab: Hong Kong's ORI hits first close on Fund II, exits Kymab
Jan 12, 2021
PharmaLeaders
Kymab: Sanofi to buy biopharmaceutical firm Kymab for up to $1.45bn
Jan 12, 2021
PMLiVE
Kymab: Sanofi gains access to antibody tech with Kymab acquisition
Jan 11, 2021
BioSpace
Kymab: Sanofi Ups Immunology Game With $1.4 Billion Acquisition of Kymab
Jan 11, 2021
THE IRISH TIMES
Kymab: Malin to make up to $145m from sale of Kymab to Sanofi
Kymab Competitors
1
2
3
4
5
6
7
8
9
10